Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative - Report - MDSpire
Advertisement
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative
Clinical Report: Long-Term Survival in HR+/HER2- Breast Cancer Patients
Overview
Revise to state that NACT is associated with inferior overall survival and breast cancer-specific survival outcomes.
Background
The management of operable HR+/HER2- breast cancer remains complex, particularly regarding the choice between NACT and ACT. Current guidelines vary, and understanding the long-term survival implications of these treatment strategies is crucial for optimizing patient outcomes. This study addresses a significant gap in the literature by focusing on stage II and T3N1M0 patients.
Data Highlights
Group
5-Year OS
5-Year BCSS
NACT
87.4%
89.3%
ACT
91.8%
93.7%
Key Findings
NACT group had a 5-year OS of 87.4% compared to 91.8% for ACT (P<0.0001).
BCSS was 89.3% for NACT versus 93.7% for ACT (P<0.0001).
Multivariate analysis showed NACT increased the risk of breast cancer-specific death (HR = 1.42, P<0.001).
NACT also increased the risk of all-cause death (HR = 1.31, P = 0.002).
Findings suggest caution in selecting NACT for operable HR+/HER2- breast cancer patients.
Clinical Implications
Healthcare professionals should carefully consider the choice of NACT versus ACT for patients with operable HR+/HER2- breast cancer, particularly for those at stage II and T3N1M0. The evidence suggests that ACT may provide better long-term survival outcomes, warranting a reevaluation of treatment protocols.
Conclusion
The study highlights the inferior survival outcomes associated with NACT compared to ACT in operable HR+/HER2- breast cancer, emphasizing the need for careful treatment selection in this patient population.
